Oral Abstract Session:
207. Hepatitis C
Saturday, October 5, 2013: 2:00 PM-3:30 PM
Room: The Moscone Center: 250-262

Learning Objectives:

-

Target Audience: infectious diseases physicians

Topical Category: V. Clinical Virology and V1. Studies of the epidemiology of viral infections

Tracks: Adult ID

Moderator:  Arthur Kim, MD, FIDSA, Massachusetts General Hospital

Presentations:

2:00 PM
Risk Behaviors Associated to HCV-infection Among Inmates in a Prison State System in Mexico
Pablo F. Belaunzaran-Zamudio, MD, MSc, DTM&H ; Juan Mosqueda-Gomez, MD ; Juan Sierra Madero, MD ; Alejandro Macías Hernández, MD MS ; Chris Beyrer, M.D., M.P.H

2:15 PM
Trends in Injected Drug Use Among High School Students in the United States, 1995-2011
Monina Klevens, DDS, MPH ; Sherry Everett Jones ; John Ward, MD

2:30 PM
Daclatasvir Combined With Peginterferon Alfa-2a and Ribavirin for 12 or 16 Weeks in Patients With Hepatitis C Virus Genotype 2 or 3 Infection: COMMAND GT 2/3 Study
Gregory Dore ; Eric Lawitz ; Christophe Hezode ; Stephen Shafran, MD ; Alnoor Ramji ; Harvey Tatum ; Gloria Taliani ; Albert Tran ; Maurizia Brunetto ; Serena Zaltron ; Simone Strasser ; Nina Weis ; Wayne Ghesquiere ; Samuel Lee ; Dominique Larrey ; Stanislas Pol ; Hugh Harley ; Jacob George ; Scott Fung ; Victor De Ledinghen ; Peggy Hagens ; David Cohen ; Elizabeth Cooney ; Stephanie Noviello ; Eric Hughes

2:45 PM
Interim Analysis of an Interferon (IFN)- And Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 In Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients
Gregory T. Everson ; Karen D. Sims ; Maribel Rodriguez-Torres, MD ; Christophe Hézode ; Eric Lawitz ; Marc Bourlière ; Veronique Loustaud-Ratti ; Vinod Rustgi ; Howard Schwartz ; Harvey Tatum ; Patrick Marcellin ; Stanislas Pol ; Paul J. Thuluvath ; Timothy Eley, PhD ; Xiaodong Wang ; Shu-Pang Huang ; Fiona Mcphee ; Megan Wind-Rotolo ; Ellen Chung ; Claudio Pasquinelli ; Dennis M. Grasela ; David F. Gardiner

3:00 PM
Determinants of Response to Pegylated Interferon and Ribavirin for Acute Hepatitis C Virus Infection in Patients with Human Immunodeficiency Virus
Leah Burke, MD ; Daniel Fierer, MD ; David Cassagnol, M.S. ; Rosanne Hijdra, B.S. ; Wouter Van Seggelen, M.D. ; Kristen Marks, MD

3:15 PM
Early Metabolic and Hepatic Lipid Gene Expression Changes in Chronic Hepatitis C Patients Treated with an Interferon-free Regimen
Eric Meissner, MD, PhD ; Anu Osinusi, MD, MPH ; Jing Qin, PhD ; Yu-Jin Lee, BA ; Susanna Naggie, MD ; Keyur Patel, MD ; John Mchutchison, MD ; Henry Masur, MD, FIDSA ; Shyam Kottilil, MD, PhD

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

A. Kim, Gilead Sciences: Scientific Advisor, Consulting fee
Vertex Pharmaceuticals: Scientific Advisor, Consulting fee
Abbvie Pharmaceuticals: Scientific Advisor, Consulting fee
Bristol-Myers Squibb: Investigator, Research grant

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.